Monte Rosa Therapeutics (GLUE) director receives 25,800 stock options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Monte Rosa Therapeutics director Andrew N. Schiff received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and were awarded as compensation, not through open-market buying or selling.

The options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options covering 25,800 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHIFF ANDREW N

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	25,800	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 25,800 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 25,800 options Exercise price: $17.10 per share Underlying shares: 25,800 shares +3 more

6 metrics

Options granted 25,800 options Stock Option (Right to Buy) grant to director

Exercise price $17.10 per share Conversion or exercise price of options

Underlying shares 25,800 shares Common stock underlying granted options

Shares after transaction 25,800 options Total derivative holdings following grant

Option expiration June 11, 2036 Expiration date of the stock options

Vesting date trigger June 11, 2027 or next annual meeting Earlier of two dates for full vesting

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 17.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable in full"

annual meeting of stockholders financial

"upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHIFF ANDREW N

(Last)

(First)

(Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON

MASSACHUSETTS

02118

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$17.1	06/11/2026		A		25,800		⁽¹⁾	06/11/2036	Common Stock	25,800	$0	25,800	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

	/s/ Markus Warmuth, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Monte Rosa Therapeutics (GLUE) disclose in this Form 4?

Monte Rosa Therapeutics reported that director Andrew N. Schiff received stock options for 25,800 common shares. These options were granted as compensation and are not open-market purchases or sales, giving him the right to buy shares at a fixed exercise price.

How many stock options did Andrew N. Schiff receive from Monte Rosa Therapeutics (GLUE)?

Andrew N. Schiff received options on 25,800 shares of Monte Rosa Therapeutics common stock. These options represent a right to buy that many shares in the future at a preset exercise price if vesting conditions are met.

What is the exercise price of Andrew N. Schiff’s Monte Rosa Therapeutics (GLUE) options?

The stock options granted to Andrew N. Schiff have an exercise price of $17.10 per share. This means he can buy Monte Rosa Therapeutics common shares at $17.10 once the options vest and become exercisable, regardless of the future market price.

When do Andrew N. Schiff’s Monte Rosa Therapeutics (GLUE) options vest?

The options vest and become exercisable in full on the earlier of June 11, 2027 or Monte Rosa Therapeutics’ next annual stockholder meeting. Vesting is conditioned on Schiff’s continued service with the company through that applicable vesting date.

Is this Monte Rosa Therapeutics (GLUE) Form 4 a market buy or sell by the director?

This Form 4 reflects a grant of stock options to director Andrew N. Schiff, not a market purchase or sale. The transaction is categorized as a grant or award acquisition, with no cash price paid per option at the grant date.

How many Monte Rosa Therapeutics (GLUE) options does Andrew N. Schiff hold after this grant?

Following this grant, Andrew N. Schiff holds options covering 25,800 underlying shares of Monte Rosa Therapeutics common stock directly. These options are subject to the disclosed vesting schedule before they can be exercised for shares.